Connect with us
Laminar Pharma raised €5.9 million, led by the Matutes family, for its growth and launch of anti-tumor drug LAM 561, aimed at glioblastoma treatment. Additional investors...
Valued at €2.4 million, Dipneo will use funds to finalize its commercial prototype and begin regulatory procedures. The autonomous, hands-free device inflates air into patients and...
FrontWave Imaging was created at the end of 2020 as a spin-off of the Barcelona Supercomputing Center and Imperial College London. In 2024, after clinical research,...
The current round has an investment commitment of up to €3 million, which includes the participation of the founding partners. The €7 million will make it...
In 2022, Better Care reached a turnover of €1 million, compared to half a million euros it achieved in 2021. By 2023, the Catalan biotech company...
Looking ahead to 2024, the group plans to reach break-even, when the European Medicines Agency approves its drug against glioblastoma, an aggressive type of cancer that...
ReHand became the first digital solution via tablet for the rehabilitation of wrist, hand, and fingers, which account for 29% of the injuries that reach hospital...
VB Devices closed 2021 with sales of $339,000 (€315,000), the target for 2022 is to achieve $977,000 (€909,000) and for 2023 to exceed $1.6 million (€1.5...
Of the total amount that Laminar Pharma estimates it needs, $10.7 million (€10 million) correspond to bank financing already agreed with Banca March. In addition, the...
With the publication of the results of this trial, which will probably take place in March or April, Neurofix Pharma will increase its valuation and will...